CTLA4 and metastatic melanoma: As a result, there have been dramatic improvements in progression-free (PFS) and overall survival (OS), particularly in metastatic melanoma, with 5-years OS rates of over 50 and 44% for those treated with combined anti-CTLA4 and anti-PD1 therapy or anti-PD-1 monotherapy, respectively (3).